SOAT1 and infection: While tofacitinib-driven inhibition of the JAK/STAT pathway leads to reduced inflammation, it can also impair immune response against infections.1,2 However, the impact of tofacitinib on mucosal immunity against enteric pathogens remains poorly understood.